BROWNSTEIN HYATT FARBER SCHRECK, LLP for BAXTER HEALTHCARE CORPORATION
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 19, 2017 | $30,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Oct 5, 2019 | $30,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Corporate tax issues, including deferral and device tax Tax reform Issues related to the border adjustment tax
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER DAHL | — |
| LORI HARJU | — |
| MICHAEL B LEVY | — |
Health Issues HCR
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATE MCCANLESS BLANKENBURG | — |
| LAURA JOHNSON BOLLIER | — |
| ALEXANDER DAHL | — |
Medicare/Medicaid MMM
Funding issues for Medicare Part B 340 B drug discount program
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATE MCCANLESS BLANKENBURG | — |
| LAURA JOHNSON BOLLIER | — |
| ALEXANDER DAHL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.